Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining chemotherapy
with hormone therapy may kill more tumor cells. Chemoprevention therapy is the use of certain
drugs to try to prevent the development or recurrence of cancer. The use of fenretinide may
be an effective way to prevent the recurrence of breast cancer. It is not yet known whether
tamoxifen plus fenretinide is more effective than tamoxifen alone for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen plus
fenretinide with tamoxifen alone in treating postmenopausal women who have stage II or stage
III breast cancer that is estrogen receptor positive and/or progesterone receptor positive.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI) North Central Cancer Treatment Group Southwest Oncology Group